Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery
Year: 2021
Type: article
Abstract: The design of effective target-specific drugs for COVID-19 treatment has become an intriguing challenge for modern science. The SARS-CoV-2 main protease, M pro , responsible for the processing of SARS-CoV-2 polyproteins and production of individual components of viral replication machinery, is an attractive candidate target for drug discovery. Specific M pro inhibitors have turned out to be promising anticoronaviral agents. Thus, an effective platform for quantitative screening of M pro -targeting molecules is urgently needed. Here, we propose a pre–steady-state kinetic analysis of the interaction of M pro with inhibitors as a basis for such a platform. We examined the kinetic mechanism of peptide substrate binding and cleavage by wild-type M pro and by its catalytically inactive mutant C145A. The enzyme induces conformational changes of the peptide during the reaction. The inhibition of M pro by boceprevir, telaprevir, GC-376, PF-00835231, or thimerosal was investigated. Detailed pre–steady-state kinetics of the interaction of the wild-type enzyme with the most potent inhibitor, PF-00835231, revealed a two-step binding mechanism, followed by covalent complex formation. The C145A M pro mutant interacts with PF-00835231 approximately 100-fold less effectively. Nevertheless, the binding constant of PF-00835231 toward C145A M pro is still good enough to inhibit the enzyme. Therefore, our results suggest that even noncovalent inhibitor binding due to a fine conformational fit into the active site is sufficient for efficient inhibition. A structure-based virtual screening and a subsequent detailed assessment of inhibition efficacy allowed us to select two compounds as promising noncovalent inhibitor leads of SARS-CoV-2 M pro .
Source: Frontiers in Pharmacology
Authors: Maria Yu. Zakharova, Alexandra A. Kuznetsova, Victoria I. Uvarova, Anastasiia D. Fomina, Liubov I. Kozlovskaya, Elena N. Kaliberda, Inna N. Kurbatskaia, Ivan V. Smirnov, Anatoly A. Bulygin, Vera D. Knorre, Olga S. Fedorova, Alexandre Varnek, Dmitry I. Osolodkin, Aydar A. Ishmukhametov, Alexey M. Egorov, Alexander G. Gabibov, Nikita A. Kuznetsov
Institutions: Russian Academy of Sciences, Pirogov Russian National Research Medical University, Institute of Bioorganic Chemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Chumakov Institute of Poliomyelitis and Viral Encephalitides, Lomonosov Moscow State University, Sechenov University, Centre National de la Recherche Scientifique, Chimie de la Matière Complexe, Université de Strasbourg, National Research University Higher School of Economics, Novosibirsk State University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
Award: G3969577304
OpenAlex ID: W4200213104
